Platinol®
Cisplatin is a first-generation platinum compound used in the treatment of testicular, bladder, ovarian, and lung cancers. Despite significant side effects, it remains a cornerstone of oncology.
| Dosage Form | IV Injectable (Solution) |
| Strength | 1 mg/mL; 50 mg, 100 mg vials |
| Storage | Store at 15–25°C. Do not refrigerate (may precipitate). Protect from light. |
| Category | Oncology |
| Availability | Available for Transfer |
Metastatic testicular tumors; metastatic ovarian tumors; advanced bladder carcinoma; NSCLC; head and neck squamous cell carcinoma.
Crosslinks with purine bases in DNA, interfering with DNA repair mechanisms and triggering apoptosis through several signaling pathways.
Each Burrard Pharmaceuticals technology transfer package for Cisplatin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.